MedTrace Logo

A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer

NCT05660213 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 750

Last updated 2025-05-20

No results posted yet for this study

Summary

This study is a multicenter, registered research aimed at evaluating the efficacy of different treatment regimens in the treatment of unresectable CNLC liver cancer stage III hepatocellular carcinoma

Conditions

Interventions

DRUG

Targeted drugs combined with anti-PD-1/PD-L1 antibodies

Targeted drugs combined with anti-PD-1/PD-L1 antibodies

DRUG

TACE (transarterial chemoembolization) combined with targeted/immunotherapy

TACE (transarterial chemoembolization) combined with targeted/immunotherapy

DRUG

Lenvatinib monotherapy

For patients weighing less than 60 kg, the recommended daily dose of this product is 8 mg (2 capsules of 4 mg), once daily; For patients weighing ≥ 60 kg, the recommended daily dose of this product is 12 mg (3 capsules of 4 mg), once daily. Treatment should be continued until disease progression or intolerable toxic reactions occur.

DRUG

Huaier granules combined with any of the above Cohorts for treatment

Oral administration of Huaier granules, 10g each time, 3 times a day, until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that there is no longer any benefit.It is recommended that the date of first use of Huaier granules be determined by the researchers, and after disease progression, the researchers and patients should jointly decide whether to continue receiving Huaier granules treatment.

Sponsors & Collaborators

  • LinkDoc Technology (Beijing) Co. Ltd.

    collaborator INDUSTRY

  • Huazhong University of Science and Technology

    collaborator OTHER

  • Fudan University

    lead OTHER

Principal Investigators

  • Jia Fan, PhD · Affiliated Zhongshan Hospital, Fudan University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-31
Primary Completion
2027-08-31
Completion
2030-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05660213 on ClinicalTrials.gov